Marianne S Muhlebach
Overview
Explore the profile of Marianne S Muhlebach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muhlebach M, Shields T, Shah K, Ansar M, Virella-Lowell I, Zhou J, et al.
Infect Control Hosp Epidemiol
. 2024 Oct;
:1-6.
PMID: 39439036
Background: Infection control guidelines for cystic fibrosis (CF) stress cleaning of environmental surfaces and patientcare equipment in CF clinics. This multicenter study measured cleanliness of frequently touched surfaces in CF...
2.
Muhlebach M, She J, Zhang E, Cogen J, Kosorok M
J Cyst Fibros
. 2024 Oct;
24(1):98-104.
PMID: 39389810
Rationale: CF care guidelines recommend chronic inhaled antibiotics for chronic Pseudomonas aeruginosa (Pa) lung infection. These medications are costly, time consuming and prescription needs may change with improved outcomes. Objectives:...
3.
Einarsson G, Sherrard L, Hatch J, Zorn B, Johnston E, McGettigan C, et al.
J Cyst Fibros
. 2023 Dec;
23(2):252-261.
PMID: 38158284
Background: Whether there is any benefit in integrating culture-independent molecular analysis of the lower airway microbiota of people with cystic fibrosis into clinical care is unclear. This study determined the...
4.
Shah K, Saiman L, LiPuma J, Kosorok M, Muhlebach M
J Cyst Fibros
. 2023 Nov;
23(2):300-305.
PMID: 37953182
Background: Care guidelines for cystic fibrosis (CF) have been developed to enhance consistent care and to improve health outcomes. We determined if adherence to CF care guidelines predicted P. aeruginosa...
5.
Ribeiro C, Higgs M, Muhlebach M, Wolfgang M, Borgatti M, Lampronti I, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36902441
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, a new series of therapeutics that correct and potentiate some classes of mutations of the CFTR, have provided a great therapeutic advantage to...
6.
De Vuyst R, Jalazo E, Tsujimoto T, Lin F, Muenzer J, Muhlebach M
J Clin Med
. 2023 Jan;
12(2).
PMID: 36675409
People with Hunter syndrome are known to be affected by a variety of airway pathologies. Treatment of Hunter syndrome with the enzyme replacement therapy (ERT) idursulfase is now the standard...
7.
Lu K, Wagner N, Velez A, Ceppe A, Conlon B, Muhlebach M
Microbiol Spectr
. 2022 Dec;
11(1):e0406122.
PMID: 36519944
Methicillin-resistant Staphylococcus aureus (MRSA) is highly prevalent in U.S. cystic fibrosis (CF) patients and is associated with worse clinical outcomes in CF. These infections often become chronic despite repeated antibiotic...
8.
Lo D, Muhlebach M, Smyth A
Cochrane Database Syst Rev
. 2022 Dec;
12:CD009650.
PMID: 36511181
Background: Cystic fibrosis is an inherited recessive disorder of chloride transport that is characterised by recurrent and persistent pulmonary infections from resistant organisms that result in lung function deterioration and...
9.
Cunningham F, Caldwell E, Mayer-Hamblett N, Goss C, Muhlebach M
ERJ Open Res
. 2022 Dec;
8(4).
PMID: 36478917
Introduction: Early eradication of methicillin-resistant (MRSA) in cystic fibrosis is desirable. Prospective studies are challenging owing to the feasibility of recruiting patients with a rare event in an orphan disease....
10.
Stoudemire W, Jiang X, Zhou J, Kosorok M, Saiman L, Muhlebach M
J Cyst Fibros
. 2022 Aug;
21(6):1013-1019.
PMID: 35963814
Background: Healthcare-associated transmission of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa occurs for people with cystic fibrosis (CF), but CF programs lack a process to monitor incidence rates (IRs). We...